Baxter International Inc.
BAXBusiness Overview
ticker: BAX step: 01 generated: 2026-05-12 source: quick-research
Baxter International Inc. (BAX) — Business Overview
Business Description
Baxter International is a global medical products and services company headquartered in Deerfield, Illinois, focused on essential hospital infrastructure — IV solutions, infusion therapies, renal care (now divested), and hospital pharmaceuticals. Following the January 2025 sale of its Kidney Care business to Carlyle Group, Baxter is a more focused medical products company operating three continuing segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. The company is the leading U.S. manufacturer of IV solutions (critical sterile fluids used in virtually every hospital) and holds dominant market share in infusion pumps, patient monitoring, and inhalational anesthetics. Baxter operates in 100+ countries with ~$10.6B in continuing operations revenue.
Revenue Model
Revenue flows from: (1) Medical Products & Therapies — IV solutions, infusion systems, surgical sealants (~50–55% of revenue); (2) Healthcare Systems & Technologies — infusion pumps, patient monitoring, digital health platforms, clinical decision support (~25–30%); and (3) Pharmaceuticals — inhalational anesthetics, injectable drugs, critical care pharmaceuticals (~15–20%). Revenue is recurring and largely non-discretionary — hospitals must buy IV solutions and infusion pump services regardless of economic conditions. Long-term contracts and group purchasing organization (GPO) agreements provide revenue visibility.
Products & Services
- IV solutions — sterile saline, dextrose, lactated Ringer's, and specialty solutions (largest U.S. market share)
- Infusion systems — SIGMA Spectrum infusion pumps, sets, needleless connectors
- Surgical sealants — TISSEEL fibrin sealant, Floseal hemostatic matrix
- Patient monitoring — Welch Allyn vital sign monitors, point-of-care diagnostics
- Anesthesia — Suprane (desflurane), Arixtra, and hospital injectable drugs
- Sharesource — cloud platform for remote management of home dialysis (legacy, post-Kidney Care divestiture)
Customer Base & Go-to-Market
Baxter sells primarily to hospitals, integrated delivery networks (IDNs), outpatient surgery centers, and specialty clinics through direct sales forces, group purchasing organizations (GPOs), and distributors. Long-term supply contracts with hospital systems provide stable, recurring revenue. International sales (~45% of revenue) serve healthcare systems across Europe, Asia-Pacific, and Latin America.
Competitive Position
Baxter is the dominant U.S. IV solutions manufacturer (duopoly with ICU Medical/B. Braun), which creates natural oligopoly pricing power in a product that is both essential and difficult to manufacture at scale (sterile manufacturing requirements). The North Cove, NC manufacturing facility is the company's largest IV solutions plant — its disruption by Hurricane Helene in 2024 illustrated both the concentration risk and the strategic irreplaceability of Baxter's production. Infusion pumps face competition from ICU Medical (post-Smiths Medical acquisition) and BD.
Key Facts
- Founded: 1931
- Headquarters: Deerfield, IL
- Employees: ~35,000 (post-Kidney Care divestiture)
- Exchange: NYSE
- Sector / Industry: Healthcare / Medical Devices & Equipment
- Market Cap: ~$8–10B (stock down ~75% from 2021 highs as of mid-2026)
Financial Snapshot
ticker: BAX step: 04 generated: 2026-05-12 source: quick-research
Baxter International Inc. (BAX) — Financial Snapshot
Income Statement Summary
| Metric | FY2022 | FY2023 | FY2024 | YoY |
|---|---|---|---|---|
| Revenue (cont. ops) | ~$8.5B | ~$10.4B | ~$10.6B | +2.7% |
| Gross Margin | ~43% | ~40% | ~38% | |
| Operating Margin | ~8% | ~5% | ~(5)% | |
| Net Income (GAAP) | ~$0.3B | ~$(0.1)B | ~$(0.6)B | N/M |
| Adj. EPS (cont. ops) | ~$2.90 | ~$2.60 | ~$2.00 | -23% |
Note: GAAP results are heavily impacted by non-cash items — FY2024 net loss of ~$(649)M included $2.13B after-tax in special items (goodwill impairment of Front Line Care and Chronic Therapies, separation-related costs, business optimization charges). Adjusted EPS from continuing operations ($2.00 in 2024) better reflects underlying operational performance. The Kidney Care (renal) business was classified as discontinued operations and sold to Carlyle in January 2025 — historical revenue comparisons are restated on a continuing-ops basis. Hurricane Helene damaged the North Cove, NC IV solutions facility in Q3 2024, cutting guidance and disrupting supply. FY2025 guidance: adj. EPS $2.45–$2.55 from continuing operations.
Cash Flow & Balance Sheet (FY2024)
| Metric | Value |
|---|---|
| Operating Cash Flow | ~$1.2B |
| Free Cash Flow | ~$0.6B |
| Cash & Equivalents | ~$2.5B (pre-Kidney Care close proceeds) |
| Total Debt | ~$10B (high leverage from Hillrom acquisition) |
| Kidney Care Sale Proceeds | ~$3.8B (closed January 2025) |
Key Ratios (approximate, FY2024)
- P/E: N/M (GAAP loss) | EV/EBITDA: ~12–14x (on adj. EBITDA)
- Adj. FCF Yield: ~6–8% | Market Cap: ~$8–10B
- Debt/EBITDA: ~5–6x (elevated; being reduced with Kidney Care proceeds)
Growth Profile
Baxter has been in restructuring mode since the challenged $12B acquisition of Hillrom (2021) which saddled the balance sheet with $10B+ in debt. The Kidney Care divestiture (January 2025, ~$3.8B) deleverages the balance sheet and narrows focus. From continuing operations, sales growth guidance of 5–6% for 2025 reflects a recovery from Hurricane Helene disruptions and improving execution. Adj. EPS is expected to recover from the $2.00 trough (2024) toward $2.45–$2.55 in 2025 as production normalizes.
Forward Estimates
- FY2025E: Revenue ~$11.2B, Adj. EPS $2.45–$2.55 (company guidance)
- FY2026E: Revenue ~$11.5–12B, Adj. EPS ~$2.70–$3.00 (consensus estimate)
- Post-Kidney Care deleveraging target: Debt/EBITDA below 3x by 2026–2027
Deeper Financial Analysis
The fundamental tier adds 9 additional research dimensions for $BAX.